Drugs / Atacicept
Trials 18 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01369628 | Jun → Nov 2011 | lupus nephritis | EMD Serono | Terminated | No outcome recorded |
| Phase 213 trials | ||||||
| Phase 2 | NCT06983028 | Jul 2025 → Nov 2027 expected | IgA glomerulonephritis, focal segmental glomerulosclerosis, nephrotic syndrome | Vera Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07020923 | May 2025 → Sep 2026 expected | IgA glomerulonephritis | Vera Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06674577 | Dec 2024 → May 2031 expected | IgA glomerulonephritis | Vera Therapeutics, Inc. | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT02808429 | Jan 2017 → Feb 2020 | IgA glomerulonephritis | EMD Serono Research & Development Institute, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02070978 | Jul 2014 → Apr 2016 | systemic lupus erythematosus | EMD Serono | Terminated | No outcome recorded |
| Phase 2 | NCT01972568 | Dec 2013 → Apr 2016 | systemic lupus erythematosus | EMD Serono | Completed | No outcome recorded |
| Phase 2 | NCT01440231 | Feb 2012 → Aug 2013 | systemic lupus erythematosus | EMD Serono | Withdrawn | No outcome recorded |
| Phase 2 | NCT00853762 | Mar → Sep 2009 | multiple sclerosis | EMD Serono | Terminated | No outcome recorded |
| Phase 2 | NCT00624468 | Jun 2008 → Sep 2009 | optic neuritis | EMD Serono | Terminated | No outcome recorded |
| Phase 2 | NCT00642902 | Apr 2008 → Sep 2009 | multiple sclerosis | EMD Serono | Terminated | No outcome recorded |
| Phase 2 | NCT00664521 | Mar 2008 → Oct 2010 | rheumatoid arthritis | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 2 | NCT00595413 | Sep 2007 → Oct 2009 | rheumatoid arthritis | EMD Serono | Completed | No outcome recorded |
| Phase 2 | NCT00430495 | Dec 2006 → Sep 2009 | rheumatoid arthritis | EMD Serono | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT00624338 | Jan 2008 → Apr 2012 | systemic lupus erythematosus | EMD Serono | Completed | No outcome recorded |
| Phase 2/3 | NCT00573157 | Dec 2007 → Apr 2009 | lupus nephritis | EMD Serono | Terminated | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04716231 | Jun 2023 → May 2025 overdue | IgA glomerulonephritis | Vera Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05609812 | Nov 2022 → Mar 2026 | lupus nephritis | Vera Therapeutics, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Atacicept | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00853762 ↗ |
| Known as | TACI-FC5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742986 ↗ |
| Known as | TACI-IG | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742986 ↗ |
| Action | Inhibit | “Atacicept is a soluble, fully human, recombinant fusion protein that inhibits B cell-stimulating factors APRIL (a proliferation-inducing ligand) and BLyS (B-lymphocyte stimulator).” PMID 22325903 ↗ Feb 20122“Tumor necrosis factor ligand superfamily member 13B inhibitor” CHEMBL1742986 ↗ “Tumor necrosis factor ligand superfamily member 13 inhibitor” CHEMBL1742986 ↗ |
| Modality | Protein / enzyme biologic | “Atacicept is a soluble, fully human, recombinant fusion protein” PMID 22325903 ↗ Feb 2012 |
| Route | Subcutaneous | “Atacicept was administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 21 weeks.” NCT00430495 ↗ |
| Target | TNFSF13 | “Tumor necrosis factor ligand superfamily member 13 inhibitor” CHEMBL1742986 ↗ |
| Target | TNFSF13B | “Tumor necrosis factor ligand superfamily member 13B inhibitor” CHEMBL1742986 ↗ |